A randomised prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer.
Malignant pleural effusion is a frequent complication of metastatic breast cancer leading to a significant degree of morbidity. Drainage of the effusion by thoracocentesis and pleurodesis with tetracycline as the sclerosing agent is an established means of symptomatic relief in these patients. To determine whether the efficacy of tetracycline pleurodesis is improved by surgical rather than medical drainage and instillation of sclerosant, 34 patients were prospectively randomised to a trial comparing the two treatment modalities, of whom 29 were evaluable for response. The total failure rate of primary pleurodesis was 13.4%, the rate of recurrence of effusion within the first month was 24%, and only 1 patient (3.4%) required repeat aspiration in that time period. There was no significant difference in the rate of recurrence or reaspiration of effusion between the two treatment groups. Although the overall survival time from treatment of effusion is significantly longer in the surgical treatment group than in the medical treatment group (P = 0.03), this is likely to be due to factors other than the method of treating the effusion. We conclude that surgical tetracycline pleurodesis has no advantage over medical tetracycline pleurodesis.
CRC Department of Medical Oncology, Charing Cross Hospital, London, U.K.
T R
TR
Evans
R C
RC
Stein
J R
JR
Pepper
J C
JC
Gazet
H T
HT
Ford
R C
RC
Coombes
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000150:complications* / Q000401:mortality; D004322:Drainage; D005260:Female; D006801:Humans; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000601:surgery*; D011379:Prognosis; D011446:Prospective Studies; D013752:Tetracycline / Q000627:therapeutic use*; D013997:Time Factors
D013752:Tetracycline